J Korean Med Sci.  2022 May;37(19):e159. 10.3346/jkms.2022.37.e159.

Diagnostic Value of Anti-Nuclear Antibodies: Results From Korean University-Affiliated Hospitals

• Kang SH
• Seo YI
• Lee MH
• Kim HA

• KMID: 2529781
• DOI: http://doi.org/10.3346/jkms.2022.37.e159

Abstract

Background
Unnecessary and inappropriate laboratory testing accounts for a significant portion of waste in health care utilization. The aim of this study was to examine the diagnostic value of the anti-nuclear antibody (ANA) test by examining the rate of ANA associated rheumatic disease (AARD) diagnosis among ANA tested and ANA positive subjects and positive predictive value (PPV) of ANA test leading to AARD diagnosis in different ANA titers and different subsets of patients in 5 hospitals affiliated with a university.
Methods
We retrospectively extracted data from all subjects who were tested for ANA from year 2010 to 2019. Those who were first evaluated at or referred to rheumatology were further evaluated with extraction of data including ANA titer and ultimate diagnosis. PPVs for ANA test were evaluated after stratification according to clinically relevant key parameters, such as patient age (younger < 65 years vs. older), sex, and requesting department.
Results
From 2010 to 2019, A total of 94,153 patients were tested for ANA, of which 13,600 (14.4% of the total) were positive. AARD was diagnosed in only 0.69% among all ANA tested patients and 4.74% among ANA positive patients. The AARD diagnosis rate of ANA positive patients varied widely from 0.1% to 8.7% by requesting department. Using cutoff values above 1:320 yielded PPVs of 15.6 and 7.8% for all AARs and systemic lupus erythematosus. The PPV was significantly higher in young age (< 65 years) and in women, and when it was requested from internal medicine vs other departments.
Conclusion
AARD was diagnosed in less than 1% of all ANA tested patients in universityaffiliated hospitals. This result shows that careful consideration before ordering the screening ANA is needed to improve the utility of the test for providers and patients and to reduce health costs spurred by unnecessary testing and its consequences.

Keyword

Anti-Nuclear Antibody; Systemic Lupus Erythematosus; Autoimmunity; Health Care Costs

Reference

1. Brownlee S, Chalkidou K, Doust J, Elshaug AG, Glasziou P, Heath I, et al. Evidence for overuse of medical services around the world. Lancet. 2017; 390(10090):156–168. PMID: 28077234.

2. Chami N, Simons JE, Sweetman A, Don-Wauchope AC. Rates of inappropriate laboratory test utilization in Ontario. Clin Biochem. 2017; 50(15):822–827. PMID: 28483406.

3. O’Sullivan JW, Stevens S, Hobbs FD, Salisbury C, Little P, Goldacre B, et al. Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. BMJ. 2018; 363:k4666. PMID: 30487169.

4. Asola R, Huhtala H, Holli K. Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer. Breast Cancer Res Treat. 2006; 100(1):77–82. PMID: 16758120.

5. Canova C, Anello P, Barbiellini Amidei C, Parolin V, Zanier L, Simonato L. Use of healthcare services at the end of life in decedents compared to their surviving counterparts: a case-control study among adults born before 1946 in Friuli Venezia Giulia. PLoS One. 2019; 14(2):e0212086. PMID: 30730965.

6. Abeles AM, Abeles M. The clinical utility of a positive antinuclear antibody test result. Am J Med. 2013; 126(4):342–348. PMID: 23395534.

7. Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, et al. Choosing wisely: the American College of Rheumatology’s Top 5 list of things physicians and patients should question. Arthritis Care Res (Hoboken). 2013; 65(3):329–339. PMID: 23436818.

8. Aygün E, Kelesoglu FM, Dogdu G, Ersoy A, Basbug D, Akça D, et al. Antinuclear antibody testing in a Turkish pediatrics clinic: is it always necessary? Pan Afr Med J. 2019; 32(1):181. PMID: 31312295.

9. Choi HW, Kwon YJ, Park JH, Lee SY, Chun S, Won EJ, et al. Evaluation of a fully automated antinuclear antibody indirect immunofluorescence assay in routine use. Front Immunol. 2020; 11:607541. PMID: 33343581.

10. Fitch-Rogalsky C, Steber W, Mahler M, Lupton T, Martin L, Barr SG, et al. Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One. 2014; 9(4):e93812. PMID: 24705829.

11. Henderson J, Bouck Z, Holleman R, Chu C, Klamerus ML, Santiago R, et al. Comparison of payment changes and choosing wisely recommendations for use of low-value laboratory tests in the United States and Canada. JAMA Intern Med. 2020; 180(4):524–531. PMID: 32040158.

12. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997; 40(9):1601–1611. PMID: 9324014.

13. Fernandez SA, Lobo AZ, Oliveira ZN, Fukumori LM, P rigo AM, Rivitti EA. Prevalence of antinuclear autoantibodies in the serum of normal blood dornors. Rev Hosp Clin Fac Med Sao Paulo. 2003; 58(6):315–319. PMID: 14762490.

14. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med. 1996; 156(13):1421–1425. PMID: 8678710.

15. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012; 64(4):475–487. PMID: 22563590.

16. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65(11):2737–2747. PMID: 24122180.

17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725.

18. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017; 76(12):1955–1964. PMID: 29079590.

19. Li X, Liu X, Cui J, Song W, Liang Y, Hu Y, et al. Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population. J Clin Lab Anal. 2019; 33(8):e22965. PMID: 31313384.

20. Menor Almagro R, Rodríguez Gutiérrez JF, Martín-Martínez MA, Rodríguez Valls MJ, Aranda Valera C, de la Iglesia Salgado JL. Association between antinuclear antibody titers and connective tissue diseases in a Rheumatology Department. Reumatol Clin. 2017; 13(3):150–155. PMID: 27221374.

21. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003; 349(16):1526–1533. PMID: 14561795.

22. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007; 56(7):2344–2351. PMID: 17599763.